The enigma of the vertical dimension
http://babel.hathitrust.org/cgi/pt?id=mdp.39015050714057;view=2up;ui=fullscreen#page/n0/mode ...
Symposium on Craniofacial Growth
core
Metabolic interactions and growth dynamics of <i>Bifidobacterium</i> strains in response to human milk oligosaccharides and lactose. [PDF]
Ratering S +6 more
europepmc +1 more source
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source
Orthodontics in an aging society
http://babel.hathitrust.org/cgi/pt?id=mdp.39015013799666;view=2up;ui=fullscreen#page/n0/mode ...
Symposium on Craniofacial Growth
core
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
Growth dynamics and compensatory mechanisms in fish under fasting and refeeding regimes. [PDF]
Khormi MA.
europepmc +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
Pilea: profiling bacterial growth dynamics from metagenomes with sketching. [PDF]
Chen X +5 more
europepmc +1 more source
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Bridging tumor growth dynamics and survival in preclinical oncology drug development - a Tumor Growth Inhibition and Time-to-Event (TGI-TTE) modeling framework. [PDF]
Niloy KK +8 more
europepmc +1 more source

